CME Group SEC Filings

Form 4 disclosure for Derek Sammann, Senior Managing Director, Global Head of Commodities Markets at CME Group (CME). The filing reports share surrender and vesting activity on September 15-16, 2025. Mr. Sammann surrendered 1,099 and 379 Class A shares to satisfy tax withholding obligations upon restricted stock vesting on those dates. The filing lists direct beneficial ownership amounts of 8,318; 11,362; and 10,983 Class A shares after respective transactions, and shows indirect holdings of 14,614 shares held by a trust and 8,336 shares held by his spouse. The form was signed on 09/17/2025.

Terrence A. Duffy, Chairman and CEO and a director of CME Group Inc. (CME), reported a purchase of 23,180 shares of Class A Common Stock on 09/15/2025 at a reported price of $258.83 per share. After the transaction he beneficially owns 90,804 shares. The Form 4 was signed on behalf of the reporting person by Margaret Austin Wright on 09/17/2025. No derivative transactions were reported.

Hilda Harris Piell, Sr. MD & Chief HR Officer at CME Group (CME), reported insider transactions on Form 4 showing share surrenders to cover tax withholding upon restricted stock vesting. On 09/15/2025 she disposed of 953 Class A shares at $258.83 each, reducing her holdings to 28,108 shares, and on the same date acquired 2,608 shares at $258.83, raising holdings to 30,716 shares. On 09/16/2025 she disposed of 325 shares at $259.83, leaving 30,391 shares beneficially owned after the reported transactions. The filing states the disposals were share surrenders to satisfy tax-withholding obligations tied to restricted stock vesting; the form was signed on 09/17/2025.

CME Group Inc. filed a Form 144 notifying of a proposed sale of 376 shares of common stock through Morgan Stanley Smith Barney LLC, for an aggregate market value of $97,368.96. The shares were acquired as restricted stock from the issuer on 09/15/2025 and the proposed sale date is 09/16/2025 on NASDAQ. The filing shows 360,377,042 shares outstanding, and the filer states they are unaware of any undisclosed material adverse information. No sales by the filer in the past three months are reported.

Sunil K. Cutinho, Chief Information Officer of CME Group Inc. (CME) reported two stock sale transactions on 08/26/2025. He sold 5,930 shares of CME Class A common stock at a weighted average price of $272.10 (prices ranged $271.69–$272.58) and sold 5,966 shares at a weighted average price of $270.85 (prices ranged $270.32–$271.21). The Form 4 shows the amount of Class A shares beneficially owned following the reported transactions as 23,406 shares on the first line and 17,440 shares on the second line. The filing was signed by an authorized representative for Mr. Cutinho and includes explanatory notes about aggregated sale prices.

Form 144 notice for CME Group, Inc. (CME) shows a proposed sale of 11,896 common shares valued at approximately $3,229,452.32, to be executed through Morgan Stanley Smith Barney on NASDAQ on 08/26/2025. The filer acquired the shares as performance shares (2,283 shares, acquired 03/15/2025) and restricted stock (9,613 shares, acquired 09/15/2020). No securities were reported sold in the past three months. The filing includes the standard representation that the seller is unaware of undisclosed material adverse information about the issuer.

CME Group Inc. (CME) Form 144 notice reports a proposed sale of 32,468 shares of Common stock through Morgan Stanley Smith Barney LLC on NASDAQ, with an aggregate market value of $200,054.83 and approximate sale date of 08/18/2025. The shares were acquired as restricted stock from the issuer on 05/02/2024 and were fully paid on that date. The filing lists 360,377,042 shares outstanding. Certain fields such as the identity or relationship of the selling person and the filing contact details are not populated in the provided text. The filer represents they are not aware of undisclosed material adverse information and affirms the signature and certification language required by Form 144.